Prof Emma Morris

Dr Emma MorrisTel: 020 3447 9712
Fax: 020 3447 9571

University College Hospital

Blood Diseases (clinical haematology)

Professional background

Professor Emma Morris, MB BChir, MA, PhD, MRCP, FRCPath.

I graduated from the University of Cambridge in 1992 and subsequently trained in general medicine at The Royal London Hospital and Guy’s Hospital in London. I then completed Specialty training in Clinical Haematology at The Royal London Hospital, Addenbrooke’s Hospital and University College London Hospital. Whilst training I gained a PhD in aspects of haematopoietic stem cell differentiation. In 2002 I was awarded my CCST in Clinical Haematology and at the same time as continued my career in Academic Medicine with a Leukaemia Research Fund Bennett Senior Fellowship. In 2007 I was appointed Senior Lecturer in Immunology and Immunotherapy at UCL, and have since remained an active consultant haematologist.
My research group focuses on novel aspects of immune therapies for haematological malignancies, predominantly cellular and gene therapy. My clinical interest is in the field of haematopoietic stem cell transplantation. I am currently secretary of the Clinical trials Committee of the British Society for Blood and Marrow Transplantation, a member of the NCRI Low Grade Lymphoma Subgroup and on the Editorial Board of the British Journal for Haematology.

Research interests

  • Bone marrow transplantation for haematological malignancies
  • Cell therapy
  • Gene therapy


KJ Thomson, EC Morris, A Bloor, G Cook, D Milligan, A Parker, C Craddock, L Yung, DC Linch, RK Chakraverty, KS Peggs, and S Mackinnon (2008). Favorable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkins Lymphoma. J Clin Oncol. 2008; In Press.

Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2008). Superiority of reduced intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transplantation. 2008 May;41(9):765-70.

Emma Morris, Dan Hart, Liquan Gao, Aristotle Tsallios, Shao-an Xue and Hans Stauss (2006). Generation of tumor-specific T-cell therapies. Blood Reviews. 2006; 2:61-9.

Karl S. Peggs, Ann Hunter, Rajesh Chopra, Anne Parker, Premini Mahendra, Donald Milligan, Charles Craddock, Ruth Pettengell, Ahmet Dogan, Kirsty J. Thomson, Emma C. Morris, Geoff Hale, Herman Waldmann, Anthony H. Goldstone, David C. Linch, and Stephen Mackinnon (2005). Clinical Evidence of a Graft-versus-Hodgkin’s Lymphoma Effect following Reduced Intensity Allogeneic Transplantation. Lancet. 365(9475):1934-41.

Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Mackinnon S (2005). Use of F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol. 128(6): 824-9.

Morris EC and Mackinnon S. (2005). Reduced Intensity Allogeneic Stem Cell Transplantation for Low Grade Non-Hodgkin’s Lymphoma. Best Pract Res Clin Haematol. 18(1): 129-142.

Morris E, Thomson KJ, Craddock C, et al. (2004). Outcome Following Alemtuzumab (CAMPATH-1H)-Containing Reduced Intensity Allogeneic Transplant Regimen for Relapsed and refractory Non-Hodgkin’s Lymphoma (NHL). Blood 104: 3865 - 3871.

Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS (2004). Reduced Intensity transplantation: where are we now? Hematol J. Vol 5. Suppl 3: S34-8.

Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S and Hale G. (2003). Pharmacokinetics of Alemtuzumab (CAMPATH-1H) Used for in vivo and in vitro T cell Depletion in Allogeneic Transplants: Relevance for Early Adoptive Immunotherapy and Infectious Complications. Blood. 2003 Jul 1;102(1):404-406.

Morris EC, Harrison G, Bailey CC, Hann IM, Hill FG, Gibson BE, Richards S, Webb DK; Medical Research Council Childhood Leukaemia Working Party. (2003). Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia. British Journal of  Haematology. Vol 120, pp 787-9.

GMC/GDC number: 3677313